Mid-season additions to flu vaccinations?

  • Thread starter berkeman
  • Start date
In summary, the quadrivalent flu vaccine this season is not doing so well. Experts had to choose one B virus, even though there are two different lineages of B viruses that both circulate during most seasons. This meant the vaccine did not protect against the group of B viruses not included in the vaccine. Adding another B virus to the vaccine aims to give broader protection against circulating flu viruses. The seasonal epidemics usually involve a number of different flu viruses occurring at different frequency. Type A viruses tend to cause a more sever illness than type B. The type A virus H3N2 is known to cause a disease associated with more complications and it is the complications that generally cause serious illness and deaths. Quite naturally the different strains tend to
  • #1
berkeman
Mentor
66,785
19,403
As you know, the flu vaccine this season is not doing so well:

https://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm

https://www.cdc.gov/flu/about/season/flu-season-2017-2018.htm

https://www.cdc.gov/flu/protect/vaccine/quadrivalent.htm
Why was quadrivalent flu vaccine developed?
For years, flu vaccines were designed to protect against three different flu viruses (trivalent). Trivalent vaccines include an influenza A (H1N1) virus, an influenza A (H3N2) virus and one influenza B virus. Experts had to choose one B virus, even though there are two different lineages of B viruses that both circulate during most seasons. This meant the vaccine did not protect against the group of B viruses not included in the vaccine. Adding another B virus to the vaccine aims to give broader protection against circulating flu viruses.

I thought the problematic strain this year is reported as the H3N2 virus, but the quote above implies that was included in the quadrivalent vaccine. Why can't they offer an additional vaccine to address the strain that is causing the low effectiveness of the vaccine? Does it take too long to culture and produce the vaccine?
 
Last edited:
Biology news on Phys.org
  • #2
H2N2 is a virus subtype, not a specific virus.
https://en.wikipedia.org/wiki/Influenza_A_virus_subtype_H3N2

A vaccine for H3N2 will only protect against the targeted parts of a particular H3N2 - and any other viruses that happen to share those parts.

Of course, over the months it takes to develop and deploy the vaccine, the target pieces can change as the virus mutates. That can leave the vaccine less effective than hoped.
 
  • Like
Likes berkeman
  • #3
It takes approximately five to six months for the first supplies of approved vaccine to become available once a new strain of influenza virus with pandemic potential is identified and isolated.
http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090806/en/

(note: this page is from 2009, so more recent technologies, like cell based or recombinant methods, may have shortened the timespan. However, the page also refers to cases of flu with pandemic potential and not the annual flu vaccine, so it probably represents the fastest possible response with less regard to cost)
 
  • Like
Likes berkeman
  • #4
Not all influenza symptoms are due to the flu virus.
This wikipedia article says the percentage of those with sympotoms having the Flu virus can vary from 14-70.
 
  • #6
Here in the UK the issue last year seemed to be that the vaccine didn't protect the elderly as well as it did other age groups.
 
  • #7
The people responsible for vaccines are also very interested in the problems of H3N2 vaccination, these are the things they have identified as important.

The seasonal epidemics usually involve a number of different flu viruses occurring at different frequency. Type A viruses tend to cause a more sever illness than type B. The type A virus H3N2 is known to cause a disease associated with more complications and it is the complications that generally cause serious illness and deaths. Quite naturally the different strains tend to result in antibody responses that are more or less effective in preventing further disease, in general terms vaccines that target Type A, H1N1 appear around 75% effective, Type B viruses around 54% and the type A H3N2 around 33%. These are population averages but are highly variable, age is a major factor. These differences are magnified in the groups most likely to have a poor vaccine response. In the case of H3N2 the elderly are particularly at risk of a poor response.

Vaccines use example viruses a subtype of a particular strain often named based on where these viruses were collected. The current H3N2 virus used in the vaccine is the B/Victoria lineage, the closer the circulating virus is to the lineage used the more effective it is, however the H3N2 virus seems to mutate at a higher rate than other flu viruses and in areas that effect immunogenicity. The current virus circulating in the US appears to be of a different lineage, the strain was around last year and the year before in the US before Australia was hit hard.

One of the most popular theories relate to vaccine production, H3N2 is harder to grow in eggs, and it may be that the adaptation to growing in eggs may may induce the changes that reduce vaccine effectiveness.
In fact these problems were foreseen based on the Australian experience and there are already available some potential fixes. There are two products available specifically for use in the elderly, one gives a higher dose another uses an adjuvant to try and increase the response rate, these as yet haven't been evaluated. There is already a move towards producing a vaccine using recombinant technology which eliminates the need for growing the virus in eggs as well as being quicker. The quadrivalent vaccine extends the range of viruses covered and there is a huge research effort trying to produce a vaccine which targets parts of the virus that are common to the whole family of flu viruses and give a more enduring immunity.
 
Last edited by a moderator:

1. What are mid-season additions to flu vaccinations?

Mid-season additions to flu vaccinations refer to the addition of new strains of the influenza virus to the existing flu vaccine during the flu season.

2. Why are mid-season additions necessary?

Mid-season additions are necessary because the influenza virus is constantly mutating and new strains may emerge during the flu season. These new strains may not be covered by the existing flu vaccine, so mid-season additions ensure that the vaccine provides protection against the latest strains.

3. How are mid-season additions determined?

Mid-season additions are determined by monitoring the spread of the influenza virus and identifying new strains that are not covered by the existing vaccine. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) are responsible for making recommendations on which strains should be included in the mid-season additions.

4. When are mid-season additions typically made?

Mid-season additions are typically made in the middle of the flu season, which usually runs from October to May. The exact timing may vary depending on when new strains are identified and when the new vaccine can be produced and distributed.

5. Are mid-season additions safe?

Yes, mid-season additions are safe. The new strains added to the flu vaccine are thoroughly tested and approved by the FDA before being included in the vaccine. Additionally, the flu vaccine itself has a long history of safety and effectiveness, and mid-season additions do not change this.

Similar threads

  • Biology and Medical
Replies
6
Views
1K
Replies
4
Views
2K
Replies
2
Views
707
  • Biology and Medical
Replies
6
Views
2K
  • Biology and Medical
Replies
2
Views
1K
Replies
5
Views
2K
  • Biology and Medical
Replies
11
Views
2K
  • Biology and Medical
Replies
4
Views
695
  • Biology and Medical
3
Replies
100
Views
6K
  • Biology and Medical
Replies
4
Views
1K
Back
Top